Followers | 130 |
Posts | 18112 |
Boards Moderated | 0 |
Alias Born | 01/16/2007 |
Sunday, September 21, 2014 3:04:55 AM
FYI:
The date before this Filing (9/16/14), HHSE Stock closed at .008
http://ih.advfn.com/p.php?pid=historical&symbol=NO%5EHHSE
ITEM 1 - MINUTES OF THE BOARD OF DIRECTORS MEETING OF SEPT. 17, 2014
A specially called meeting of the Company's Board of Directors was held at 9:00 am on Wednesday, September 17, 2014 at the Company's principal headquarters in Springdale, AR. The following minutes cover the single agenda item which was discussed, and the actions taken as noted.
1). OFFICER PURCHASE OF RESTRICTED COMMON STOCK SHARES
The Board reviewed the proposal as set forth by each of Eric F. Parkinson and D. Frederick Shefte, in their capacity as individuals, for the purchase of restricted stock shares at $.031 per share. Based on the current “open-market” share price for Common Stock (trading at less than $.01 per share), the Board agreed that the offer to purchase shares at $.031, and to hold these shares under Rule 144 Restrictions, was beneficial to the Company and to other shareholders. Accordingly, the Board agreed to accept a direct purchase issuance in the amount of two-hundred-thousand-dollars (USD $200,000) each from Parkinson and from Shefte, for the purchase of 6,451,613 shares each, said shares to be issued as 144 Restricted Common Stock shares and to be issued to Parkinson and Shefte or to their applicable designees. Parkinson and Shefte each indicated their intention to hold the shares for at least two years, or until such time that the share price has surpassed the $.031/share initial target price threshold and achieved any other Rule 144 Restrictions regarding sale and notice. It is understood that both Parkinson and Shefte shall be required to file Form 4 Statements with the S.E.C. to report this transaction.
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=126637
http://www.otcmarkets.com/stock/HHSE/filings
HHSE
Recent HHSE News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 07:17:02 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM